Use of Sacubitril/Valsartan in Chronic Heart Failure
Use of Sacubitril/Valsartan in Chro...

By neville@docmode.com | December 1, 2023

Dr. Mriganka Baruah Medicine Specialist &; Diabetologist, MBBS, MD (Medicine) Rehed. No13898 (AMC), Fellowship in Diabetes (CMC, Vellore), Fell...

Effect of Sacubitril-Valsartan in CKD End-stage
Effect of Sacubitril-Valsartan in C...

By neville@docmode.com | December 1, 2023

Dr. Vishalkumar Vanani MBBS, MD, Medicine, DNB Cardiology (Jaslok Hospital,Mumbai), Dr. Vishal Heart Care, Comprehensive Cardiovascular Clinic. &nb...

Safety and effectiveness of sodium–glucose cotransporter-2 inhibitors and angiotensin receptor-neprilysin inhibitor for patients with heart failure with reduced ejection fraction
Safety and effectiveness of sodium–...

By neville@docmode.com | November 30, 2023

Dr. Kanish Bansal MBBS, MD (Internal Medicine), PGDDM (UK), Consultant Physician and Diabetolgist, Chandigarh   This review examines the effec...

SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction
SGLT2 Inhibitors and Heart Failure ...

By neville@docmode.com | September 8, 2023

Recent clinical trials with SGLT2 inhibitors like empagliflozin and dapagliflozin have shown significant cardiovascular benefits and reduced heart ...

2023 Guidelines for Chronic Coronary Disease Management: A Report from the American Heart Association and American College of Cardiology Joint Committee on Clinical Practice Guidelines.
2023 Guidelines for Chronic Coronar...

By neville@docmode.com | September 8, 2023

This guideline offers a patient-centered approach to managing chronic coronary disease, considering social factors and emphasizing shared decision-...

Exploring Incretins and Their Role in Cardiovascular Health in Type 2 Diabetes
Exploring Incretins and Their Role ...

By neville@docmode.com | September 8, 2023

GLP-1 receptor agonists (GLP-1RAs), regardless of their similarity to GLP-1, offer substantial cardiovascular protection in individuals with type 2...